Anti-SEZ6 Antibody-Drug Conjugates for Refractory Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapeutic treatments for solid tumors, including small cell lung cancer (SCLC), high-grade central nervous system tumors, and high-grade neuroendocrine carcinomas, are often ineffective, necessitating the development of more targeted and potent therapies.
Innovation Solution
Administration of an anti-SEZ6 antibody drug conjugate (ADC) comprising a SEZ6-targeting antibody conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload, specifically designed for intravenous use in treating solid tumors such as SCLC, CNS tumors, and neuroendocrine tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic treatments are used for solid tumors, then treatment simplicity is maintained, but treatment effectiveness deteriorates
Solution Approach 1:
The patent employs antibody-drug conjugates (ADCs) which are composite structures combining a targeting antibody with a cytotoxic drug payload. The antibody component provides tumor-specific targeting through SEZ6 antigen recognition, while the drug component delivers potent cytotoxic activity. This composite approach enables simultaneous achievement of targeted delivery (improving effectiveness) and controlled drug release (managing complexity), resolving the contradiction between treatment effectiveness and therapy complexity.
2Reliability
If targeted therapy with anti-SEZ6 ADC is administered, then treatment effectiveness improves, but dosing regimen complexity increases
Solution Approach 1:
The patent establishes specific dosing parameters including dose levels (1.3-3.5 mg/kg), administration intervals (every 3 weeks), and maximum cumulative doses based on body surface area. These quantified parameters transform the complex biological interaction of ADC therapy into manageable, standardized dosing regimens. By defining precise parameter ranges and adjustment criteria, the patent makes the targeted therapy operable in clinical practice while maintaining its effectiveness, thus resolving the contradiction between treatment effectiveness and dosing simplicity.
Data Source
AI summary
The present application pertains to, among other things, improved methods of treating advanced solid tumors, including small cell lung cancer (“SCLC”), relapsed/refractory (R/R) SCLC, high-grade central nervous system (“CNS”) tumors (glioblastoma (“GBM”), IDH-wild-type Grade 4; oligodendroglioma, IDH-mutant, and 1p/19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4), and high-grade neuroendocrine carcinomas/neuroendocrine tumors (“NECs/NETs”), using an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”). In specific embodiments, the anti-SEZ6 ADC consists of a SEZ6-targeting antibody conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.